A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Abiraterone acetate (Primary) ; Dexamethasone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Cougar Biotechnology
- 05 May 2009 Actual patient number (44) added as reported by ClinicalTrials.gov.
- 03 Jun 2008 Interim results presented at the American Society of Clinical Oncology (ASCO) 2008.
- 06 Jun 2007 Interim results presented at ASCO.